share price under 5c since 2012, page-3

PAB was 'nothing' last year and therefore the SP was less than half a cent. The buyout of deoximab technology from Yale and the progress in the past 6 months has changed everything. It has shown to target, enter and kill cancer cells and breach the brain barrier in lab tests. This hope gives us a $40 million valuation at current price. As progress is made the market cap will rise to $ 100s of millions. This is a once in a life opportunity if it works. Therefore comparing to past 6 years is ridiculous and shows lack of critical thinking.
Brainy